帕博利珠单抗二线治疗晚期肝细胞癌:KEYNOTE-240随机双盲III期试验
KEYNOTE-240研究在27个国家119个中心随机纳入413例索拉非尼经治的晚期肝细胞癌患者,按2:1接受帕博利珠单抗或安慰剂联合最佳支持治疗。结论认为OS和PFS未达统计学显著性,但结果与KEYNOTE-224一致,支持 favorable 风险获益比。
要点
- 帕博利珠单抗二线治疗晚期HCC的OS和PFS未达预设统计学显著性阈值。
- 中位OS 13.9个月 vs 10.6个月(HR 0.781,95%CI 0.611-0.998)。
- ≥3级不良事件发生率52.7% vs 46.3%,治疗相关≥3级AE 18.6% vs 7.5%。
核心结论
- 帕博利珠单抗对比安慰剂在索拉非尼经治晚期HCC中未达到预设的OS和PFS统计学显著性标准。
- 结果与II期KEYNOTE-224一致,支持帕博利珠单抗在该人群具有 favorable 的风险获益比。
研究设计与样本
- 随机、双盲、III期研究,在27个国家119个医疗中心开展。
- 413例索拉非尼经治的晚期肝细胞癌患者按2:1随机接受帕博利珠单抗+最佳支持治疗或安慰剂+最佳支持治疗。
主要发现
- 中位随访时间帕博利珠单抗组13.8个月,安慰剂组10.6个月。
- ≥3级不良事件帕博利珠单抗组147例(52.7%)vs 安慰剂组62例(46.3%);治疗相关≥3级不良事件分别为52例(18.6%)和10例(7.5%);未发现丙肝或乙肝 flare。
临床怎么用
- 帕博利珠单抗二线治疗索拉非尼经治晚期HCC虽未达预设统计学阈值,但结果显示OS和PFS数值上优于安慰剂且安全性可控,风险获益比 favorable。
- 治疗相关≥3级不良事件帕博利珠单抗组18.6%,安慰剂组7.5%,临床需关注免疫相关不良反应监测。
局限性
- OS和PFS均未达到预设的统计学显著性阈值,研究结果为阴性。
- 随访时间帕博利珠单抗组13.8个月、安慰剂组10.6个月,两组随访不均衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Pembrolizumab demonstrated antitumor activity and safety in the phase II KEYNOTE-224 trial in previously treated patients with advanced hepatocellular carcinoma (HCC). KEYNOTE-240 evaluated the efficacy and safety of pembrolizumab in this population. PATIENTS AND METHODS: This randomized, double-blind, phase III study was conducted at 119 medical centers in 27 countries. Eligible patients with advanced HCC, previously treated with sorafenib, were randomly assigned at a two-to-one ratio to receive pembrolizumab plus best supportive care (BSC) or placebo plus BSC. Primary end points were overall survival (OS) and progression-free survival (PFS; one-sided significance thresholds, P = .0174 [final analysis] and P = .002 [first interim analysis], respectively). Safety was assessed in all patients who received ≥ 1 dose of study drug. RESULTS: Between May 31, 2016, and November 23, 2017, 413 patients were randomly assigned. As of January 2, 2019, median follow-up was 13.8 months for pembrolizumab and 10.6 months for placebo. Median OS was 13.9 months (95% CI, 11.6 to 16.0 months) for pembrolizumab versus 10.6 months (95% CI, 8.3 to 13.5 months) for placebo (hazard ratio [HR], 0.781; 95% CI, 0.611 to 0.998; P = .0238). Median PFS for pembrolizumab was 3.0 months (95% CI, 2.8 to 4.1 months) versus 2.8 months (95% CI, 2.5 to 4.1 months) for placebo at the first interim analysis (HR, 0.775; 95% CI, 0.609 to 0.987; P = .0186) and 3.0 months (95% CI, 2.8 to 4.1 months) versus 2.8 months (95% CI, 1.6 to 3.0 months) at final analysis (HR, 0.718; 95% CI, 0.570 to 0.904; P = .0022). Grade 3 or higher adverse events occurred in 147 (52.7%) and 62 patients (46.3%) for pembrolizumab versus placebo; those that were treatment related occurred in 52 (18.6%) and 10 patients (7.5%), respectively. No hepatitis C or B flares were identified. CONCLUSION: In this study, OS and PFS did not reach statistical significance per specified criteria. The results are consistent with those of KEYNOTE-224, supporting a favorable risk-to-benefit ratio for pembrolizumab in this population.
引用
- Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol. 2019. PMID: 31790344. doi:10.1200/JCO.19.01307
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。